Crossmark

Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation

Published Online: 2018-05-25

Published Print: 2018-11

Authors

Gao, Lan

Li, Shu-Chuen
Funding

Funding for this research was provided by:

Teva Pharma Australia Pty Ltd
License Information

Text and Data Mining valid from 2018-05-25
More Information

Article History

Received: 3 October 2017

Accepted: 19 May 2018

First Online: 25 May 2018

Compliance with ethical standards

:

: Authors confirm that there is no conflict of interest to declare.

Document is current